Physician profile
Donna Hooks
NPI 1083053045
$3,137.50
in general payments reported to CMS, 2019-2025
33 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,846 · 2022: $874 · 2023: $55.61 · 2024: $184 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.21 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.54 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $265.58 | 2021-2024 | |
| Glaxosmithkline, LLC. | $239.65 | 2021-2022 | |
| Lilly USA, LLC | $204.68 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $194.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $165.83 | 2021-2023 | |
| Pfizer INC. | $153.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $136.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $128.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $126.10 | 2022 | |
| Astellas Pharma US INC | $119.71 | 2021 | |
| Ferring Pharmaceuticals INC. | $105.24 | 2021-2022 | |
| Amarin Pharma, INC. | $99.15 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $91.15 | 2021-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $85.01 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.90 | 2021-2022 | |
| Exact Sciences Corporation | $71.80 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $68.36 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.63 | 2021-2022 | |
| Abbott Laboratories | $59.52 | 2022 | |
| Vertos Medical, INC. | $47.07 | 2021 | |
| Boston Scientific Corporation | $46.51 | 2025 | General - Pain Management |
| Ucb, INC. | $43.43 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.58 | 2024 | |
| Sanofi Pasteur INC. | $33.36 | 2021-2022 | |
| Almatica Pharma LLC | $28.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.66 | 2021 | |
| Nevro Corp. | $23.59 | 2022 | |
| Spr Therapeutics, INC | $21.61 | 2024 | Sprint Pns System |
| Sunovion Pharmaceuticals INC. | $20.19 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.99 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.94 | 2021 | |
| Dexcom, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Hooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.